메뉴 건너뛰기




Volumn 189, Issue 6, 2004, Pages 964-970

A 48-week duration of therapy with pegylated interferon α2b plus ribavirin may be too short to maximize long-term response among patients infected with genotype-1 hepatitis C virus

Author keywords

[No Author keywords available]

Indexed keywords

CREATINE; REBETRON;

EID: 1642328395     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/382279     Document Type: Article
Times cited : (80)

References (8)
  • 1
    • 0033584440 scopus 로고    scopus 로고
    • The prevalence of hepatitis C virus infection in the United States, 1988 through 1994
    • Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341:556-62.
    • (1999) N Engl J Med , vol.341 , pp. 556-562
    • Alter, M.J.1    Kruszon-Moran, D.2    Nainan, O.V.3
  • 2
    • 0035934568 scopus 로고    scopus 로고
    • Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial
    • Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358:958-65.
    • (2001) Lancet , vol.358 , pp. 958-965
    • Manns, M.P.1    McHutchison, J.G.2    Gordon, S.C.3
  • 3
    • 0037179698 scopus 로고    scopus 로고
    • Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection
    • Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975-82.
    • (2002) N Engl J Med , vol.347 , pp. 975-982
    • Fried, M.W.1    Shiffman, M.L.2    Reddy, K.R.3
  • 4
    • 0036795976 scopus 로고    scopus 로고
    • Ribavirin dosing in chronic hepatitis C: Application of population pharmacokinetic-pharmacodynamic models
    • Jen J, Laughlin M, Chung C, et al. Ribavirin dosing in chronic hepatitis C: application of population pharmacokinetic-pharmacodynamic models. Clin Pharmacol Ther 2002; 72:349-61.
    • (2002) Clin Pharmacol Ther , vol.72 , pp. 349-361
    • Jen, J.1    Laughlin, M.2    Chung, C.3
  • 5
    • 0016916438 scopus 로고
    • Prediction of creatinine clearance from serum creatinine
    • Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16:31-41.
    • (1976) Nephron , vol.16 , pp. 31-41
    • Cockcroft, D.W.1    Gault, M.H.2
  • 6
    • 0032547938 scopus 로고    scopus 로고
    • Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
    • Hepatitis Interventional Therapy Group
    • McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339:1485-92.
    • (1998) N Engl J Med , vol.339 , pp. 1485-1492
    • McHutchison, J.G.1    Gordon, S.C.2    Schiff, E.R.3
  • 7
    • 0032585237 scopus 로고    scopus 로고
    • Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
    • International Hepatitis Interventional Therapy Group
    • Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group. Lancet 1998; 352:1426-32.
    • (1998) Lancet , vol.352 , pp. 1426-1432
    • Poynard, T.1    Marcellin, P.2    Lee, S.S.3
  • 8
    • 0012619455 scopus 로고    scopus 로고
    • Peginterferon alfa-2a (40KD) (Pegasys) in combination with ribavirin (RBV): Efficacy and safety results from a phase III, randomized, double blind, multicenter study examining effect of duration of treatment and RBV dose
    • abstract 536. Madrid
    • Hadziyannis SJ, Cheinquer H, Morgan T, et al. Peginterferon alfa-2a (40KD) (Pegasys) in combination with ribavirin (RBV): efficacy and safety results from a phase III, randomized, double blind, multicenter study examining effect of duration of treatment and RBV dose [abstract 536]. 37th Annual Meeting of the European Association for the Study of the Liver (Madrid). 2002.
    • (2002) 37th Annual Meeting of the European Association for the Study of the Liver
    • Hadziyannis, S.J.1    Cheinquer, H.2    Morgan, T.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.